Search Result

Results for "

peptide-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (16) CGRP Receptor (4) Formyl Peptide Receptor (FPR) (4) Natriuretic Peptide Receptor (NPR) (2) Peptide-Drug Conjugates (PDCs) (1) ADC Linker (1) Akt (4) Amino Acid Derivatives (11) AMPK (1) Angiotensin Receptor (7) Angiotensin-converting Enzyme (ACE) (3) Antibiotic (1) Apoptosis (7) Arrestin (1) Autophagy (1) Bacterial (6) Bcl-2 Family (1) Biochemical Assay Reagents (30) Calcium Channel (2) Calmodulin (1) CaSR (7) Cathepsin (1) CD47 (1) Cholinesterase (ChE) (1) Collagen (2) Complement System (1) Deubiquitinase (1) Dipeptidyl Peptidase (27) Drug Derivative (3) Drug Intermediate (6) Endogenous Metabolite (19) ERK (13) Estrogen Receptor/ERR (1) FAAH (1) Fluorescent Dye (10) Fungal (1) G Protein-coupled Receptor Kinase (GRK) (1) Gap Junction Protein (2) GCGR (60) GLP Receptor (87) Glucocorticoid Receptor (1) Glycoprotein VI (2) Glycosidase (1) GnRH Receptor (4) GPR119 (5) GPR35 (1) GSK-3 (3) HCV (3) HCV Protease (3) Histamine Receptor (1) HIV (3) Huntingtin (1) IFNAR (1) Insulin Receptor (9) Integrin (2) Interleukin Related (4) Isotope-Labeled Compounds (12) JNK (1) mAChR (1) MEK (3) MHC (2) MMP (5) nAChR (1) NADPH Oxidase (1) Neuropeptide Y Receptor (1) NF-κB (3) NO Synthase (2) NOD-like Receptor (NLR) (2) Opioid Receptor (1) p38 MAPK (2) PCSK9 (1) Phosphodiesterase (PDE) (1) PI3K (1) PKA (11) PKC (1) PROTACs (1) Protease Activated Receptor (PAR) (7) Proteasome (2) Ras (1) Reactive Oxygen Species (ROS) (5) Reference Standards (15) SARS-CoV (3) Ser/Thr Protease (1) Sirtuin (1) Src (3) Tau Protein (1) TGF-beta/Smad (5) TREM receptor (1) TRP Channel (3) Tyrosine Hydroxylase (1) Vasopressin Receptor (1) Wnt (1)
By Research Areas:	Cancer (28) Cardiovascular Disease (34) Endocrinology (7) Infection (17) Inflammation/Immunology (35) Metabolic Disease (163) Neurological Disease (53)
Click Chemistry:	TCO (1)
Oligonucleotides:	Polymers (2)

352

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

246

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: RXFP Receptor Formyl Peptide Receptor (FPR) Peptide-Drug Conjugates (PDCs) Natriuretic Peptide Receptor (NPR) Connective Peptide CGRP Receptor Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3506

Retatrutide 3 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity ^[1].

HY-P0014

Liraglutide 35+ Cited Publications	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-112185

Orforglipron 1 Publications Verification LY3502970; GLP-1 receptor agonist 1	GCGR	Metabolic Disease Inflammation/Immunology
Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete ^[1].

HY-P0264

Exendin(9-39) amide 30+ Cited Publications Avexitide	GLP Receptor	Metabolic Disease
Exendin(9-39) amide (Avexitide) is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for binding to *GLP-1* receptors, thereby antagonizing the effects of excess *GLP-1* secretion. Exendin(9-39) amide can be used to study postoperative hypoglycemia (PBH) ^[1].

HY-125824

Danuglipron 4 Publications Verification PF-06882961	GCGR	Metabolic Disease
Danuglipron (PF-06882961) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron has the potential for type 2 diabetes research ^[1] .

HY-P0120

Dulaglutide 1 Publications Verification LY2189265	GCGR	Metabolic Disease
Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) ^[1] .

HY-P0054A

GLP-1(7-36), amide 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide; Human GLP-1 (7-36), amide	GCGR	Metabolic Disease
GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretion.

HY-13443A

Exendin-4 acetate Maximum Cited Publications 66 Publications Verification Exenatide acetate	GCGR	Cardiovascular Disease Metabolic Disease Cancer
Exendin-4 acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC₅₀ of 3.22 nM.

HY-160734

Aleniglipron GSBR-1290	GLP Receptor	Metabolic Disease
Aleniglipron (GSBR-1290) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist, with an EC₅₀ value of less than 0.1 nM in HDB cell lines in cAMP stimulation assays. Aleniglipron selectively activates the Gαs-cAMP signaling pathway of *GLP-1R* without β-arrestin recruitment. Aleniglipron induces insulin release, promotes glucose clearance, reduces food intake and decreases body weight. Aleniglipron is applicable to research related to type 2 diabetes and obesity ^[1] .

HY-P0054

GLP-1(7-36), amide acetate 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate	GCGR	Metabolic Disease
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-P3506A

Retatrutide TFA 3 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity ^[1].

HY-103546

BETP 1 Publications Verification	GCGR	Metabolic Disease
BETP is an agonist of *glucagon-like peptide-1* (GLP-1) receptor, with EC₅₀*s of 0.66 and 0.755 μM for human and rat GLP*-1 receptor, respectively.

HY-112185A

Orforglipron hemicalcium hydrate 1 Publications Verification LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate	GCGR	Metabolic Disease Inflammation/Immunology
Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete ^[1].

HY-13443

Exendin-4 Maximum Cited Publications 66 Publications Verification Exenatide	GCGR	Cardiovascular Disease Metabolic Disease Cancer
Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC₅₀ of 3.22 nM.

HY-129658A

TT-OAD2	GCGR	Metabolic Disease
TT-OAD2 is a non-peptide *glucagon-like peptide-1* (GLP-1) receptor agonist with an EC₅₀** of 5 nM. TT-OAD2 has the potential for diabetes treatment ^[1] .

HY-156968

GLP-1 receptor agonist 14	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 14 (compound 474) is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 14 plays an important role in diabetes or other metabolic disorders ^[1].

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) ^[1] .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) ^[1] .

HY-P1145

*Glucagon-like peptide 1* (1-37), human** 1 Publications Verification GLP-1 (1-37) human	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.

HY-P0054B

GLP-1(7-36), amide TFA 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA	GCGR	Metabolic Disease
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells ^[1].

HY-P10957

Imapextide MBX 1416	GLP Receptor	Metabolic Disease
Imapextide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that can be used in hypoglycemia research ^[1].

HY-112679

GLP-1 receptor agonist 2	GCGR	Inflammation/Immunology
GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor *(GLP-1R)* agonist ^[1].

HY-145458

PF-06954522 GLP-1 receptor agonist 9	GLP Receptor	Metabolic Disease
PF-06954522 is a glucagon-like peptide-1 receptor (GLP-1R) agonist. PF-06954522 is applicable to research related to type 2 diabetes ^[1].

HY-N0630

Shanzhiside methyl ester 1 Publications Verification	GCGR	Neurological Disease
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule *glucagon-like peptide-1* (GLP-1) receptor** agonist and has the ability to induce anti-allodynic tolerance ^[1].

HY-142162

LSN3318839	GCGR	Metabolic Disease
LSN3318839 is an orally active positive modulator of the glucagon-like peptide-1 receptor (GLP-1R). LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar ^[1].

HY-P10929

Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH	Drug Intermediate	Others
Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH is a drug intermediate in the synthesis of Tirzepatide. Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor (GLP-1R) agonist ^[1].

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting *glucagon-like peptide-1* receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R)** dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects ^[1] .

HY-P1145A

*Glucagon-like peptide 1* (1-37), human TFA** 1 Publications Verification HuGLP-1 TFA	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.

HY-P3414A

*Proteasome-activating peptide 1* TFA** 3 Publications Verification	Proteasome	Neurological Disease
Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis ^[1].

HY-P1805

Calmodulin Binding Peptide 1	Calmodulin	Neurological Disease
Calmodulin Binding Peptide 1 is a high-affinity (pM) CaM-binding peptide derived from smooth muscle myosin light chain kinase (MLCK peptide). The interface of the complex formed by Calmodulin Binding Peptide 1 and Ca ²⁺-CaM can be specifically bound by small-molecule inhibitors, serving as a key target for selective regulation of smooth muscle contraction and development of anti-CaM drugs ^[1].

HY-P0014S1

Liraglutide-13C5,15N tetraTFA	Isotope-Labeled Compounds GLP Receptor GCGR	Others
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) ^[1]. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10888A

*GPC3 targeting peptide 1* TFA**	Glycoprotein VI	Cancer
GPC3 targeting peptide 1 TFA is a GPC3 targeting peptide, with a K_d value of 0.23 nM ^[1] .

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes ^[1] .

HY-P5815

GLP-1 (1-36) amide (human, rat) Glucagon-like peptide 1 (1-36) amide (human, rat)	GLP Receptor GCGR	Metabolic Disease
GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells ^[1].

HY-P10723

IL-23R inhibitor peptide-1	Interleukin Related	Inflammation/Immunology
IL-23R inhibitor peptide-1 (comp 475) is an interleukin-23 receptor inhibitor, with an IC₅₀ of 0.0069 μM ^[1].

HY-143312

V-0219	GLP Receptor	Metabolic Disease Inflammation/Immunology
V-0219 is an orally active glucagon-like peptide-1 receptor (GLP-1R) positive allosteric modulator. V-0219 potentiates *GLP-1R* stimulation, and enhances GLP-1-induced cAMP production and insulin secretion. V-0219 potentiates glucose-dependent insulin secretion. V-0219 improves glucose handling in normal and diabetic rodents. V-0219 can be used for the research of obesity-associated diabetes ^[1].

HY-139276

Pal-Glu(OSu)-OH	GLP Receptor	Others
Pal-Glu(OSu)-OH is a side chain of Liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used for type 2 diabetes mellitus research ^[1].

HY-P4858

*C-Peptide 1* (rat)**	GSK-3 Wnt	Cancer
C-Peptide 1 (rat), a peptide, is aβ-catenin/GSK-3β activator. C-Peptide 1 (rat) can regulate the Wnt/β-catenin signaling pathway. C-Peptide 1 (rat) can be used for the research of cancer ^[1].

HY-P10269

Bofanglutide GZR18	GLP Receptor	Metabolic Disease
Bofanglutide (GZR18) is an analog of glucagon-like peptide-1 (GLP-1), which exhibits agonistic activity for GLP-1 receptor, with an EC₅₀ of 0.677 nM. GZR18 ameliorates type 2 diabetes ^[1].

HY-P10888

GPC3 targeting peptide 1	Glycoprotein VI	Cancer
GPC3 targeting peptide 1 is a GPC3 targeting peptide, with a K_d value of 0.23 nM ^[1] .

HY-P0264A

Exendin(9-39) amide acetate 30+ Cited Publications Avexitide acetate	GLP Receptor	Metabolic Disease
Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research ^[1].

HY-P10414A

*Klotho-derived peptide 1* hydrochloride** KP1 (human) hydrochloride	TGF-beta/Smad p38 MAPK	Inflammation/Immunology
Klotho-derived peptide 1 (KP1 human) hydrochloride blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model ^[1].

HY-P5815A

GLP-1 (1-36) amide (human, rat) TFA Glucagon-like peptide 1 (1-36) amide (human, rat) TFA	GLP Receptor GCGR	Metabolic Disease
GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) TFA is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) TFA can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells ^[1].

HY-P3586

HKPao Hunter-killer peptide ao; Prohibitin-targeting peptide 1; prohibitin-TP01; Adipotide	Apoptosis	Cancer
HKPao (Hunter-killer peptide ao) is a biologically active peptide. HKPao (Hunter-killer peptide ao) has anti-obesity and anti-tumor pro-apoptotic activity to cause release of cytochrome c from vesicles ^[1].

HY-108795

Albiglutide fragment GLP-1-Gly8; GLP-1 (7-36) analog	GLP Receptor	Metabolic Disease
Albiglutide fragment (GLP-1 (7-36) analog) is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting *GLP-1* receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies ^[1] .

HY-143312A

V-0219 hydrochloride	GLP Receptor	Metabolic Disease Inflammation/Immunology
V-0219 hydrochloride is an orally active glucagon-like peptide-1 receptor (GLP-1R) positive allosteric modulator. V-0219 hydrochloride potentiates *GLP-1R* stimulation, and enhances GLP-1-induced cAMP production and insulin secretion. V-0219 hydrochloride potentiates glucose-dependent insulin secretion. V-0219 hydrochloride improves glucose handling in normal and diabetic rodents. V-0219 hydrochloride can be used for the research of obesity-associated diabetes ^[1].

HY-103433

K579	Dipeptidyl Peptidase	Metabolic Disease
K579 is a potent and orally active dipeptidyl peptidase IV inhibitor. K579 inhibits the blood glucose elevation. K579 increases the plasma insulin and active forms of glucagon-like peptide-1 (GLP-1). K579 has the potential for the research of diabetic ^[1].

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research ^[1].

HY-P1520

*Prolactin Releasing Peptide (1-31), human*	GnRH Receptor	Neurological Disease
Prolactin Releasing Peptide (1-31), human is a high affinity GPR10 ligand that cause the release of the prolactin. Prolactin Releasing Peptide (1-31) binds to GPR10 for human and rats with K_i values of 1.03 nM and 0.33 nM, respectively. Prolactin Releasing Peptide (1-31) can be used for the research of the hypothalamo-pituitary axis ^[1] .

HY-P1520A

*Prolactin Releasing Peptide (1-31), human acetate*	GnRH Receptor	Neurological Disease
Prolactin Releasing Peptide (1-31), human (acetate) is a high affinity GPR10 ligand that causes the release of the prolactin. Prolactin Releasing Peptide (1-31) binds to GPR10 for human and rats with K_i values of 1.03 nM and 0.33 nM, respectively. Prolactin Releasing Peptide (1-31) can be used for the research of the hypothalamo-pituitary axis ^[1] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-D0843

N-Ethylmaleimide Maximum Cited Publications 37 Publications Verification NEM	Microorganisms Source Classification	Cathepsin Deubiquitinase Apoptosis
N-Ethylmaleimide (NEM) derives from maleic acid, it can alkylates free sulfhydryl. N-Ethylmaleimide is an irreversible cysteine protease inhibitor. N-ethylmaleimide specific inhibits phosphate transport in mitochondria. N-Ethylmaleimide inhibits prolyl endopeptidase with an IC₅₀ value of 6.3 μM. N-Ethylmaleimide can be used to modify cysteine residues in proteins and peptides .

HY-W011121

2-Oleoylglycerol 1 Publications Verification 2-OG	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Lipid Source Classification	GPR119 NF-κB TGF-beta/Smad GLP Receptor
2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC₅₀ value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the *GPR119/TAK1/NF-κB/TGF-β1* signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) ^[1] .

HY-N0630

Shanzhiside methyl ester 1 Publications Verification	Iridoids Terpenoids Labiatae Phaseolus lunatus L. Plants Source Classification	GCGR
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule *glucagon-like peptide-1* (GLP-1) receptor** agonist and has the ability to induce anti-allodynic tolerance ^[1].

HY-P0277

Carcinoembryonic antigen peptide 1 CEA peptide	Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Others
Carcinoembryonic antigen peptide 1 (CEA peptide) is a carcinoembryonic antigen (CEA)-derived peptide. Carcinoembryonic antigen peptide 1 is a potential HLA-A*0201-restricted CTL epitope that can be used for the study of CTL-mediated epithelial-derived cancers ^[1].

HY-W587803

Propionylglycine	Source Classification	Amino Acid Derivatives
Propionylglycine is a peptide .

HY-N12513

Cyclo(L-Phe-trans-4-OH-L-Pro)	Natural Products Microorganisms Source Classification	Fungal
Cyclo(L-Phe-trans-4-OH-L-Pro) is an antifungal peptides .

HY-N0630R

Shanzhiside methyl ester (Standard)	Structural Classification Iridoids Terpenoids Labiatae Phaseolus lunatus L. Plants Source Classification	Reference Standards GCGR
Shanzhiside methyl ester (Standard) is the analytical standard of Shanzhiside methyl ester. This product is intended for research and analytical applications. Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance ^[1].

HY-119640

Aspercolorin	Alkaloids Microorganisms Classification of Application Fields Cyclopeptides Other Diseases Pyridine Alkaloids Disease Research Fields Source Classification	Endogenous Metabolite
Aspercolorin, a secondary metabolite, is a cyclic peptide .

HY-113513

5-HEPE	Microorganisms Source Classification	Others
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

HY-N18033

Glyceollin III	Structural Classification Monophenols Leguminosae Glycine max (L.) merr Phenols Plants Source Classification	Insulin Receptor GLP Receptor
Glyceollin III is a glyceollin found in soybeans. Glyceollin III enhances insulin-stimulated glucose uptake and increases glucagon-like peptide-1 (GLP-1) secretion. Glyceollin III can be used for the research of type 2 diabetes ^[1].

HY-N13945

Argyrin G	Natural Products Microorganisms Source Classification	Others
Argyrin G is a natural cyclic, non-ribosomal peptide .

HY-N13948

Argyrin H	Natural Products Microorganisms Source Classification	Others
Argyrin H is a natural cyclic, non-ribosomal peptide .

HY-N13942

Argyrin E	Natural Products Microorganisms Source Classification	Others
Argyrin E is a natural cyclic, non-ribosomal peptide .

Cat. No.	Product Name	Chemical Structure

HY-P0014S1

Liraglutide-13C5,15N tetraTFA
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) ^[1]. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-13749AS

Sitagliptin-d4 phosphate

Sitagliptin-d₄ phosphate (MK-0431-d₄) is the deuterium labeled Sitagliptin phosphate (HY-13749A). Sitagliptin phosphate is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes.

HY-13749S1

Sitagliptin-d4 hydrochloride

Sitagliptin-d₄ hydrochloride is the deuterium labeled Sitagliptin hydrochloride (HY-13749E). Sitagliptin hydrochloride is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin hydrochloride blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin hydrochloride can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin hydrochloride shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin hydrochloride can be used for the study of 1-type and 2-type diabetes.

HY-P0014AS

Liraglutide-d8 tetraTFA
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a *glucagon-like peptide-1* (GLP-1) receptor** agonist used for the study of type 2 diabetes mellitus ^[1].

HY-P1363S

β-Amyloid-15N (1-42), human TFA
β-Amyloid- ¹⁵N (1-42), human (TFA) is the ¹⁵N-labledβ-Amyloid (1-42) (TFA). β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease ^[1].

HY-P0014S2

Liraglutide-13C6,15N TFA
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus ^[1].

HY-13443S

Exendin-4 (Leu-13C6,15N) TFA
Exendin-4 (Leu- ¹³C₆, ¹⁵N) (Exenatide (Leu- ¹³C₆, ¹⁵N)) TFA is the ¹³C- and ¹⁵N-labeled Exendin-4 TFA (HY-13443). Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC₅₀ of 3.22 nM ^[1].

HY-10235S

Telaprevir-d4
Telaprevir-d₄ is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CLpro activity .

HY-P1363S1

β-Amyloid (1-42), human, Ala(13C3,15N) TFA

β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death ^[1] ^[1] .

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA

Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis ^[1] .

HY-13749S2

Sitagliptin-d4

Sitagliptin-d₄ (MK-0431-d₄) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.

HY-13749S3

Sitagliptin-d6

Sitagliptin-d₆ (MK-0431-d₆) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.

HY-W754054

Propionylglycine (Standard)-13C2,15N
Propionylglycine (Standard)- ¹³C₂, ¹⁵N is the ¹³C- and ¹⁵N-labeled Propionylglycine (HY-W587803). Propionylglycine is a peptide .

HY-W701772

2-Oleoylglycerol-d5

2-Oleoylglycerol-d₅ (2-OG-d₅) is the deuterium labeled 2-Oleoylglycerol (HY-W011121). 2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC₅₀ value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) ^[1] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks